ENA Connection vs SnakeBite911

ENA Connection is published 11 times per year from January to December and is the official magazine of the Emergency Nurses Association. As a direct benefit for ENA members, this publication reaches over 40,000 emergency nurses from 35 countries. This application is powered by GTxcel, a leader in digital publishing technology, provider of hundreds of online digital publications and mobile magazine apps.

*New app! This new SnakeBite911 consolidates an older suite of apps (SnakeBite911ER, SnakeBite911FR and SnakeBite911) into one tool. It features a refreshed design and a new emergency mode for quick access to core functionality.* This useful guide can help educate you about North American venomous pit viper snakes (including rattlesnakes, copperheads and cottonmouths), how to best avoid them, and what to do and what NOT to do should a snake strike happen! This app also works without signal. Features • Emergency support for snakebite emergencies • Quick dial 911 • List of actions you should/shouldn’t take in supporting the snakebite victim • Venom Tracker photo tool to log the spread of venom, which can help save diagnostic and treatment time when the victim gets to the ER • Learn about North American venomous snakes and how to identify them • Learn how to keep safe from snakes and avoid being bitten The new SnakeBite911 app comes from the manufacturers of CroFab® CrotalidaePolyvalent Immune Fab (Ovine), a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Do not administer CroFab® to patients with a known hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. WARNINGS AND PRECAUTIONS Coagulopathy: In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required re-hospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug. Hypersensitivity Reactions: Severe hypersensitivity reactions may occur with CroFab®. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CroFab®. Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia). ADVERSE REACTIONS The most common adverse reactions (incidence ≥ 5% of subjects) reported in the clinical studies were urticaria, rash, nausea, pruritus and back pain. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Recurrent coagulopathy due to envenomation and requiring additional treatment may occur. Find out more at www.CroFab.com, which includes the full Prescribing Information. To report suspected adverse reactions, contact 1-877-377-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.